Sauti Project Quarterly Progress Report FY 19 Q2 Report January 1‐ March 31, 2019 Submitted: April 30, 2019 Sauti Project FY19 Q2 Progress Report i Sauti Project is a five-year cooperative agreement funded by the U.S. Agency for International Development under Cooperative Agreement AID-621-A-15-00003. Jhpiego Corporation implements the Sauti Project with its partners, EngenderHealth, Inc., Pact, Inc., and the National Institute for Medical Research (NIMR). Sauti Project supports and advances implementation of the US President’s Plan for AIDS Relief by providing a package of core services to Key and Vulnerable Populations (KVP) in support of the Government of the United Republic of Tanzania’s commitment to HIV prevention. This publication is made possible by the support of the American people through the US Agency for International Development (USAID) under the terms of Cooperative Agreement AID-621-A-15-0000-3. The contents are the responsibility of Jhpiego/Sauti Project and do not necessarily reflect the views of USAID or the US Government. Sauti Project FY 19 Q2 Progress Report ii TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................ iii LIST OF ACRONYMS .............................................................................................................. v EXECUTIVE SUMMARY .......................................................................................................... 7 FY19 Q2 ACHIEVEMENTS ....................................................................................................... 8 Objective 1: Biomedical ........................................................................................................ 19 Objective 2: SBCC/Gender .................................................................................................. 19 Objective 2: WORTH+ ......................................................................................................... 19 Objective 3: Research and Learning Agenda ...................................................................... 20 Objective 4: Engagement of CSOs, LGAs and Sustainability ........................................... 20 Objective 5: M&E ................................................................................................................... 20 DREAMS ................................................................................................................................ 21 QA/QC ................................................................................................................................... 22 KEY ACTIVITIES AND NEW STRATEGIES IN Q2, FY19 ............................................................. 23 Objective 1: Implement a package of core and expanded biomedical HIV prevention and FP interventions, with enhanced linkages to care and treatment, and support services . 23 Objective 2: Deploy interventions designed to reduce individual risk behaviors and strengthen support for positive social norms and structures, and address gender at the community level .................................................................................................................... 26 SBCC AND GENDER INTERVENTIONS ............................................................................................... 26 STRUCTURAL INTERVENTIONS ......................................................................................................... 32 Objective 3: Execute a Robust Research and Learning Agenda .......................................... 37 OBJECTIVE 4: Increase the sustainability of comprehensive HIV prevention services by strengthening engagement and ownership of host government, CSOs, and communities 43 Quality Assessment (QA) and Quality Improvement (QI) Services ................................ 44 Support KVPFS at Government of Tanzania (GOT) health facilities under PPP (EJAF/OGAC) ........................................................................................................................ 45 Objective 5: Build and deploy vigorous monitoring and evaluation systems .................... 47 Determined Resilient AIDS‐free Mentored Safe (DREAMS) Initiative ............................... 49 PROGRAM MANAGEMENT .................................................................................................. 53 Personnel ...................................................................................... Error! Bookmark not defined. Regional Office Management ....................................................... Error! Bookmark not defined. Procurement ................................................................................. Error! Bookmark not defined. Sub award Management ....................................................................................................... 53 Strategic Partnerships and Cost Share Opportunities ...................................................... 53 Sauti Project FY19 Q2 Progress Report iii Finance ................................................................................................................................... 53 LESSONS LEARNT ................................................................................................................. 54 Biomedical.............................................................................................................................. 54 SBCC and Gender .................................................................................................................... 55 WORTH+ ................................................................................................................................. 56 Research and Learning Agenda ............................................................................................ 57 M&E ......................................................................................................................................... 57 DREAMS .................................................................................................................................. 57 QA/QC ..................................................................................................................................... 57 CHALLENGES, OPPORTUNITIES AND WAYFOWARD ............................................................. 58 Biomedical.............................................................................................................................. 58 SBCC and Gender .................................................................................................................... 59 WORTH+ ................................................................................................................................. 59 Research and Learning Agenda ............................................................................................ 59 M&E ......................................................................................................................................... 60 DREAMS .................................................................................................................................. 60 QA/QC ..................................................................................................................................... 60 PLANNED ACTIVITIES FOR FY 19 Q3 ..................................................................................... 60 Biomedical.............................................................................................................................. 60 SBCC and Gender .................................................................................................................... 61 WORTH+ ................................................................................................................................. 62 Research and Learning Agenda ............................................................................................ 62 Capacity Building/CSOs ......................................................................................................... 63 M&E ......................................................................................................................................... 63 DREAMS .................................................................................................................................. 64 QA/QC ..................................................................................................................................... 64 APPENDICES ........................................................................................................................ 65 Appendix 1: Success Story ................................................................................................... 65 Appendix 2: FP Commodities requested and received ..................................................... 66 Appendix 3: Regional Meetings Held in Q2 ....................................................................... 67 Sauti Project FY18 Q2 Report iv LIST OF ACRONYMS AGYW Adolescent girls and young women ART Antiretroviral therapy CBHSP Community based health service providers CBHTC+ Community-based HIV testing and counseling plus CHMT Council health management team CISP Comprehensive Institutional Strengthening Plan COE Center of excellence CSO Civil society organization CRF Client Register Form CT Care and Treatment CTC Care and treatment clinic D4D Data for development DC District Council DH Digital health DHIS District health